Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Neurodegeneration, NASH, and ADC Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CTSB drug discovery and ADC linker cleavage assays. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Active Enzyme (Mature) | CTSB Recombinant Protein (Active Form), High purity (>95%), Sequence Verified, Z-Arg-Arg-AMC substrate reactive. Endotoxin <1EU/µg. | View CTSB Products |
| Pro-Enzyme (Zymogen) | Pro-Cathepsin B (Zymogen), auto-activation capable, HEK293 Expressed, Native Glycosylation. | View CTSB Products |
| Ortholog Panel | CTSB (Human / Mouse / Cyno), species cross-reactivity evaluation set for preclinical safety. | View CTSB Products |
| Selectivity Panel | Cathepsin Family Proteins (L, S, K), strictly verified by Mass Spec for off-target liability screening. | View CTSL Products |
| Gene Delivery | CTSB Promise-ORF / Lentivirus, full-length ORF for stable cell line construction. | View CTSB Products |
| Benchmark Antibody | Anti-CTSB Recombinant Antibody, sequence-defined positive control for binding assays. | View CTSB Products |
| Validator | CTSB siRNA Set, for knockdown verification and specificity confirmation. | View CTSB Products |
| Biological Context | TIMP1 (Natural Inhibitor), endogenous regulatory control reference. | View TIMP1 Products |
| Related Target A | CTSL (Cathepsin L), homolog counter-screening and alternative cleavable linker mechanism. | View CTSL Products |
| Related Target B | CTSS (Cathepsin S), subfamily selectivity counter-screening and off-target liability assessment. | View CTSS Products |
| Related Target C | MMP9 (Matrix Metallopeptidase 9), tumor microenvironment protease network partner. | View MMP9 Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ADC Linker Cleavage Validation | Human/Mouse ortholog proteins available with >95% purity, Sequence Verified; concentrated mature CTSB for in vitro peptide linker hydrolysis kinetics. |
| Subfamily Selectivity (CTSL/CTSS/CTSK Off-target) | Homolog Panel proteins available with >95% purity, Sequence Verified by Mass Spec, Theoretical MW confirmed. |
| pH-Dependent Activity Profiling (Lysosomal pH 4.5 vs Neutral pH 7.4) | Active CTSB with consistent specific activity across pH 3.0-8.0 range; Buffer compatibility validated. |
| Pro-Enzyme Activation Kinetics | Pro-CTSB Zymogen (Theoretical MW 37kDa) with auto-catalytic processing capability under acidic conditions. |
| Species Cross-reactivity (Cyno/Mouse Preclinical) | Human/Mouse/Cyno ortholog proteins with >90% sequence homology, Endotoxin Controlled (<1EU/µg). |
| Assay Specificity Controls / Mechanism Confirmation | Clinical Benchmark Antibodies included; Validated siRNA for target-specificity confirmation in cellular assays. |
Live CTSB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Cathepsin B is transitioning from broad-spectrum cysteine protease inhibition to highly selective, indication-specific strategies. While first-generation small molecules faced challenges with off-target toxicity related to Cathepsin L/S cross-reactivity, the current pipeline emphasizes differentiated modalities including tumor-activated prodrugs, lysosomal targeting chimeras (LYTACs), blood-brain barrier penetrant inhibitors for neurodegeneration, and utilization of CTSB as a universal enzymatic trigger for Antibody-Drug Conjugates (ADCs). As the understanding of CTSB's role in immune modulation and extracellular matrix remodeling deepens, combination therapies with checkpoint inhibitors and precision ADC payloads are emerging as critical development vectors. Additionally, activity-based probes for cancer diagnostics and TME imaging represent an expanding frontier.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (Cleavable Linker) | Seagen, Daiichi Sankyo, AstraZeneca | Solid Tumors (HER2, TROP2) | Enzymatic Cleavage Assay (Need high-purity mature CTSB + stable cell lines) |
| Small Molecule Inhibitor | Novartis, AstraZeneca, Vertex, ViroBay | Solid Tumors, NASH, Fibrosis, Alzheimer's | Selectivity Panel (CTSL/CTSS/CTSK) + pH-dependent activity assays |
| Prodrug / Tumor-Microenvironment Activated Agents | Cleavage-dependent ADC payloads, early-stage pharma | Breast, Lung Cancer | Release Kinetics Assay (Need active CTSB + Pro-CTSB activation kinetics) |
| Antibody/Peptide Inhibitors | Academic consortia, Biotech | Inflammation, Fibrosis | Heterophilic binding assays using Human/Mouse/Cyno ortholog proteins |
| siRNA/ASO | Alnylam, Ionis (exploratory) | Neurodegeneration | CTSB ORF Lentivirus for stable cell line construction |
| Activity-Based Probe | Academic Consortia, Chemical Biology Labs | Cancer Diagnostics, TME Imaging | Active Site Integrity Confirmation (Need WT vs Mutant controls) |